icon bookmark-bicon bookmarkicon cameraicon checkicon chevron downicon chevron lefticon chevron righticon chevron upicon closeicon v-compressicon downloadicon editicon v-expandicon fbicon fileicon filtericon flag ruicon full chevron downicon full chevron lefticon full chevron righticon full chevron upicon gpicon insicon mailicon moveicon-musicicon mutedicon nomutedicon okicon v-pauseicon v-playicon searchicon shareicon sign inicon sign upicon stepbackicon stepforicon swipe downicon tagicon tagsicon tgicon trashicon twicon vkicon yticon wticon fm

Genomics startup sold 5mn users’ genetic data to big pharma

Genomics startup sold 5mn users’ genetic data to big pharma
A major DNA-testing Silicon Valley company is partnering with a British pharmaceutical giant, saying its database of over five million hereditary material samples will help develop new medical treatments.

The $300 million four-year collaboration project between GlaxoSmithKline (GSK) and 23andMe genomics company will allow the London-based pharmaceutical to use over five million DNA samples from the genetic-phenotypic database of the Mountain View firm.

“The goal of the collaboration is to gather insights and discover novel drug targets driving disease progression and develop therapies for serious unmet medical needs based on those discoveries,” 23andMe said in a statement.

Noting “commercialization expertise of GSK,” as well as the company's capabilities to research and develop new drugs, 23andMe expressed hope that their database will be used “across a broad range of diseases and modalities, including small molecule, biopharmaceuticals and cell and gene therapies.”

In 2007, 23andMe pioneered DNA saliva-based testing for ancestry. Besides offering its customers the possibility of discovering their roots, the company employed scientific researchers to analyze the customer data, which was then repeatedly used for scientific research.

The firm gets the consent of its customers before using the samples in this way. While the individual can protect their privacy, “any of your data that have already been entered into a study cannot be withdrawn, but your data will not be included in studies that start more than 30 days after you withdraw,” the terms say.

“For those who do consent, their information will be de-identified, so no individual will be identifiable to GSK,” the pharmaceutical said, noting that over 80 percent of 23andMe’s customer base on average consent to participate in research.

While some experts, like Peter Pitts, president of the Center for Medicine in the Public Interest, questioned potential privacy breaches, GSK was quick to assure that protection of customers’ data and privacy is the highest priority.

“Both companies have stringent security protections in place when it comes to collecting, storing and transferring information about research participants. 23andMe employs software, hardware and physical security measures to protect the computers where data is stored and information will only be transferred using encryption to offer maximum security,” GSK said.

Like this story? Share it with a friend!

Dear readers and commenters,

We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system.

Sorry for the inconvenience, and looking forward to your future comments,

RT Team.